


Olaparib SOLO-2

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Only improved PFS mature data shows no OS advantage and no improved QoL



Olaparib SOLO-2

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Maintenance therapy in patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChT

Experimental Arm: Olaparib

Control Arm: Placebo



